Welcome to LookChem.com Sign In|Join Free
  • or
2-(4-methoxybenzyl)-2H-tetrazole-5-carbonyl chloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

100245-19-0

Post Buying Request

100245-19-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

100245-19-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 100245-19-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,2,4 and 5 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 100245-19:
(8*1)+(7*0)+(6*0)+(5*2)+(4*4)+(3*5)+(2*1)+(1*9)=60
60 % 10 = 0
So 100245-19-0 is a valid CAS Registry Number.

100245-19-0Relevant academic research and scientific papers

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

-

, (2016/08/23)

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

-

, (2012/05/21)

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 100245-19-0